SAB Biotherapeutics, Inc 10-Q for FY2026 Q3
SAB Biotherapeutics, Inc. (SABS)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
SAB Biotherapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
SAB-142 received FDA Fast Track designation for new-onset Stage 3 T1D in October 2026, while SAFEGUARD expanded enrollment to pediatric patients ages 5-11 in September 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $22.3M
- compared with net income of $45.45M a year earlier
- Diluted EPS
- -$0.24
- compared with -$0.21 a year earlier